Biological activity of residual cell-substrate DNA.
Vaccines and other biological products manufactured in cells contain contaminating residual DNA derived from that production cell substrate, with the amount and form of this DNA depending mainly on the type of vaccine. The potential risk of this cellular DNA has been debated for over 40 years without resolution. Opinions on residual DNA have varied from it being considered an inert contaminant, and thus its presence should not be deemed to be a risk to vaccine recipients, to it being considered an important risk factor, particularly for vaccines manufactured in certain cell substrates, such as cells derived from tumours or cells that are tumorigenic. We are not of the opinion that DNA can be considered biologically inert, but whether or what risk residual cell-substrate DNA poses remains to be determined. In this paper, we discuss our approaches to address this issue and describe some preliminary work.
Peden
K
K
Division of Viral Products, OVRR, CBER, FDA, Bethesda, MD 20892, USA. peden@cber.fda.gov
Sheng
L
L
Pal
A
A
Lewis
A
A
D002273:Carcinogens; D003470:Culture Media / Q000009:adverse effects*; D004247:DNA / Q000633:toxicity*; D004273:DNA, Neoplasm / Q000633:toxicity; D004279:DNA, Viral / Q000633:toxicity; D015658:HIV Infections / Q000517:prevention & control / Q000635:transmission; D006801:Humans; D009369:Neoplasms / Q000517:prevention & control; D015183:Restriction Mapping; D012190:Retroviridae / Q000235:genetics; D014162:Transfection; D014612:Vaccines
D002273:Carcinogens; D003470:Culture Media; D004273:DNA, Neoplasm; D004279:DNA, Viral; D014612:Vaccines; D004247:DNA